A Phase 3 interventional study of Brexpiprazole (OPC-34712) and Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-12-20.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 16 in phase 3, and was the 23rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 316 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 33rd largest by enrollment of the 111 interventional ones that give a count, is one of 10 that started in 2017, is one of 50 in phase 3, and was the 82nd registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
This is a multicenter, randomized, double-blind, placebo- and active-controlled trial to evaluate the safety and efficacy of brexpiprazole monotherapy compared to placebo in adolescent subjects (ages 13-17) with a DSM-5 diagnosis of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered with brexpiprazole oral tablets, daily, dose titrated up to 0.5 mg by Day 4, 1 mg by Day 7, 2 mg by Day 14, then between 2-4 mg after Day 21 up to Week 6 with a 1 mg increase or decrease, based on the Investigator's decision.
Drug: Brexpiprazole (OPC-34712)
Participants were administered with aripiprazole oral tablets, daily, dose titrated up to 2 mg by Day 4, 5 mg by Day 7, 10 mg by Day 14, then 10, 15 or 20 mg after Day 21 up to Week 6 with a 5 mg increase or decrease, based on the Investigator's decision.
Drug: Aripiprazole
Participants were administered with brexpiprazole or aripiprazole matching placebo oral tablets, daily up to Week 6.
Drug: Placebo
Once-daily, tablets
Once-daily, tablets
Once-daily, tablets
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) to 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranges from 30 (best possible outcome) to 210 (worst possible outcome). Higher scores indicate worsening of symptoms. Least squares (LS) mean was determined by Mixed-effect model repeated measures (MMRM) method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value and baseline visit interaction as a covariate, and with an unstructured covariance.
Time frame: Baseline to Week 6
Change From Baseline to Week 6 in PANSS Positive and Negative Sub-Scales Scores
PANSS has 7 positive symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility; and 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. Each item's severity was rated on 7-point scale, with score of 1 (absence of symptoms) to 7 (extremely severe symptoms). PANSS positive \& negative subscale scores were the sum of rating scores for 7 positive \& 7 negative items respectively. Both scores range from 7 (best possible outcome) to 49 (worst possible outcome). Higher scores denote worsening of symptoms. LS mean was determined by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.
Time frame: Baseline to Week 6
Percentage of Participants Achieving Response
Response was defined as at least 30% improvement from baseline in PANSS Total Score or CGI score of 1 or 2. The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel, and ranges from 30 (best possible outcome) to 210 (worst possible outcome). The CGI scale is an investigator-rated evaluation that assesses the severity of a participant's illness on a 7-point scale, ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Percentage of participants achieving response was determined by Last Observation Carried Forward (LOCF) method.
Time frame: Up to 6 weeks
Percentage of Participants Achieving Remission
Remission was defined as a score of ≤ 3 on each of the following specific PANSS items: delusions (positive scale item \[P\] 1), unusual thought content (general scale item \[G\] 9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (negative scale item \[N\] 1), passive/apathetic social withdrawal (N4), and lack of spontaneity and conversation flow (N6). Each item's severity was rated on 7-point scale, with score of 1 (absence of symptoms) to 7 (extremely severe symptoms). Percentage of participants achieving remission was determined by LOCF method.
Time frame: Up to 6 weeks
Change From Baseline to Week 6 in Children's Global Assessment Scale (CGAS) Total Score
The CGAS is a 100-point rating scale measuring psychological, social, and school functioning for children aged 6-17 years and provides a global measure of the severity of disturbance. The scale is separated into 10-point sections that are headed with a description of the level of functioning and followed by examples matching the interval. The score ranges from 0-100, 1 to 10 indicates the need for constant supervision and 91 to 100 indicates superior functioning in all areas. Higher scores indicate better functioning. LS mean was determined by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.
Time frame: Baseline to Week 6
Change From Baseline to Week 6 in Clinical Global Impression Severity (CGI-S) Scale Score
The CGI-S scale is an investigator-rated evaluation that assesses the severity of a participant's illness on a 7-point scale, ranging from 1 to 7. The investigator answered the question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?". Response choices were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. Higher scores indicate worse condition. LS mean was determined by the MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.
Time frame: Baseline to Week 6
Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 6
The efficacy of brexpiprazole in the treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was entirely due to drug treatment on a 7-point scale, ranging from 0 to 7. Response choices were: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Higher scores indicate worse condition. Mean CGI-I scale score was determined by LOCF method.
Time frame: Week 6
Number of Participants With Adverse Events (AEs) and Trial Discontinuation Due to AEs
An AE was defined as any untoward medical occurrence in a participant administered with a medicinal product that does not necessarily have a causal relationship with the treatment.
Time frame: From the first dose of study drug up to 21 days after the last dose of study drug (up to approximately 9 weeks)
Number of Participants With Treatment-emergent AEs (TEAEs), Serious TEAEs, and TEAEs Graded by Severity
An AE was defined as any untoward medical occurrence in a participant administered with a medicinal product that does not necessarily have a causal relationship with the treatment. An SAE was any AE that results in the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions which is fatal, life-threatening, result in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, and requires inpatient hospitalization or prolongation of existing hospitalization. TEAE is any AE after the start of treatment or if the event was continuous from baseline, medicinal product related, or resulted in death, discontinuation, interruption or reduction of medicinal product. TEAEs were graded on a 3-point scale: 1 (Mild: Discomfort noticed, but no disruption to daily activity), 2 (Moderate: Discomfort sufficient to reduce or affect normal daily activity), and 3 (Severe: Inability to work or perform normal daily activity).
Time frame: From the first dose of study drug up to 21 days after the last dose of study drug (up to approximately 9 weeks)
Mean Change From Baseline in Weight
Change in weight was reported, in kilograms (kg).
Time frame: Baseline up to last visit (approximately 6 weeks)
Mean Change From Baseline in Height
Change in height was reported in centimeters (cm).
Time frame: Baseline up to last visit (approximately 6 weeks)
Mean Change From Baseline in Body Mass Index (BMI)
Change in BMI was reported in kilograms per square meter (kg/m\^2).
Time frame: Baseline up to last visit (approximately 6 weeks)
Mean Change From Baseline in Waist Circumference
Change in waist circumference was reported in 'cm'.
Time frame: Baseline up to last visit (approximately 6 weeks)
Number of Participants With At Least One Occurrence of Suicidal Behavior or Suicidal Ideation as Recorded on Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a scale used to report at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any of the following items: actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior. The suicidal ideation total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) and the total score ranges from 0 to 25. Lower scores indicate improvement.
Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Number of Participants With Potentially Clinically Relevant Laboratory Test Values
Potentially clinically relevant laboratory values assessed included - serum chemistry \[including blinded prolactin\], hematology, and urinalysis as defined in SAP.
Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Number of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs
Vital sign measurements included body weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Blood pressure measurements were made in the supine, sitting, and standing positions after the participant had been in each position for at least 3 minutes as defined in SAP.
Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters
Twelve-lead ECG recordings were obtained after the participant was supine and at rest for at least 5 minutes as defined in SAP.
Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Change From Baseline in Simpson Angus Scale (SAS) Total Score
The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where lower scores indicate less severe condition. LS mean was determined by Analysis of Covariance (ANCOVA) model with treatment and study center as main effects and baseline value as covariate.
Time frame: Baseline up to last visit (approximately 6 weeks)
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
The AIMS assessment consists of 12 items rating the involuntary movements: Facial and oral movements (4 items), extremity movements (2 items), and trunk movements (1 item) were observed unobtrusively while the participant is at rest and the investigator also made global judgments on the participant's dyskinesias (2 items), and dental status (2 items). Severity of each item was rated on a 5-point scale, with a score of 0 (absence of symptoms) to 4 (severe condition). Total Score is the sum of the scores of all 12 items, ranging from 0 to 48, higher scores indicate severe condition. LS mean was determined by ANCOVA model with treatment and study center as main effects and baseline value as covariate.
Time frame: Baseline up to last visit (approximately 6 weeks)
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14, higher scores indicate severe condition. LS mean was determined by ANCOVA model with treatment and study center as main effects and baseline value as covariate.
Time frame: Baseline up to last visit (approximately 6 weeks)
Number of Participants With Severe Psychotropic Side Effects as Assessed by Udvalg for Kliniske Undersogelser (UKU) Rating Scale
The UKU rating scale is a semi-structured interview used to assess the side effects of participants being treated with antipsychotic drugs. The scale is divided into 6 sub-scales: Psychic, neurological, autonomic, other, global assessment by subject, and global assessment by doctor. The scale has a total of 48 items, each item is rated on a 4-point scale (0=not present; 1=mild; 2=moderate; 3=severe), and the total score ranges from 0 to 144. Higher ratings indicate greater impairment. The severe side effects are reported in this outcome measure.
Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Number of Participants With Cognitive Adverse Effects Assessed by New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)
The NY-AACENT is used to detect changes in cognitive function subsequent to pharmacological or similar treatments for neurological or psychiatric problems, specifically designed to be used in pediatric population (ages 12 to 17), but could have been utilized with other age groups, as appropriate. Number of participants with at least one occurrence of the corresponding signs/symptoms are reported in this outcome measure.
Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Participants took part in the study at investigational sites in the United States, Mexico, France, Italy, Poland, Romania, Serbia, Spain, Ukraine, and Russia from 30 June 2017 to 03 April 2023.
| Milestone | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Started | 110 | 102 | 104 |
| Safety sample | 110 | 102 | 104 |
| Efficacy sample | 110 | 101 | 103 |
| Completed | 107 | 97 | 92 |
| Not completed | 3 | 5 | 12 |
| Withdrew: Adverse event | 0 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 |
| Withdrew: Withdrawal by caregiver | 1 | 3 | 5 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) to 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranges from 30 (best possible outcome) to 210 (worst possible outcome). Higher scores indicate worsening of symptoms. Least squares (LS) mean was determined by Mixed-effect model repeated measures (MMRM) method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value and baseline visit interaction as a covariate, and with an unstructured covariance.
| score on a scale | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score | -22.75 ± 1.49 | -23.95 ± 1.57 | -17.42 ± 1.58 |
PANSS has 7 positive symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility; and 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. Each item's severity was rated on 7-point scale, with score of 1 (absence of symptoms) to 7 (extremely severe symptoms). PANSS positive \& negative subscale scores were the sum of rating scores for 7 positive \& 7 negative items respectively. Both scores range from 7 (best possible outcome) to 49 (worst possible outcome). Higher scores denote worsening of symptoms. LS mean was determined by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.
| score on a scale | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Change From Baseline to Week 6 in PANSS Positive Sub-scale Score | -6.58 ± 0.43 | -7.29 ± 0.45 | -5.14 ± 0.46 |
| Change From Baseline to Week 6 in PANSS Negative Sub-scale Score | -4.70 ± 0.41 | -4.77 ± 0.43 | -3.82 ± 0.44 |
Response was defined as at least 30% improvement from baseline in PANSS Total Score or CGI score of 1 or 2. The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel, and ranges from 30 (best possible outcome) to 210 (worst possible outcome). The CGI scale is an investigator-rated evaluation that assesses the severity of a participant's illness on a 7-point scale, ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Percentage of participants achieving response was determined by Last Observation Carried Forward (LOCF) method.
| percentage of participants | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving Response | 43.64 | 43.56 | 28.16 |
Remission was defined as a score of ≤ 3 on each of the following specific PANSS items: delusions (positive scale item \[P\] 1), unusual thought content (general scale item \[G\] 9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (negative scale item \[N\] 1), passive/apathetic social withdrawal (N4), and lack of spontaneity and conversation flow (N6). Each item's severity was rated on 7-point scale, with score of 1 (absence of symptoms) to 7 (extremely severe symptoms). Percentage of participants achieving remission was determined by LOCF method.
| percentage of participants | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving Remission | 29.09 | 35.64 | 23.30 |
The CGAS is a 100-point rating scale measuring psychological, social, and school functioning for children aged 6-17 years and provides a global measure of the severity of disturbance. The scale is separated into 10-point sections that are headed with a description of the level of functioning and followed by examples matching the interval. The score ranges from 0-100, 1 to 10 indicates the need for constant supervision and 91 to 100 indicates superior functioning in all areas. Higher scores indicate better functioning. LS mean was determined by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.
| score on a scale | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Change From Baseline to Week 6 in Children's Global Assessment Scale (CGAS) Total Score | 10.56 ± 1.00 | 12.07 ± 1.05 | 8.08 ± 1.06 |
The CGI-S scale is an investigator-rated evaluation that assesses the severity of a participant's illness on a 7-point scale, ranging from 1 to 7. The investigator answered the question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?". Response choices were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. Higher scores indicate worse condition. LS mean was determined by the MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.
| score on a scale | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Change From Baseline to Week 6 in Clinical Global Impression Severity (CGI-S) Scale Score | -0.92 ± 0.09 | -1.01 ± 0.09 | -0.80 ± 0.09 |
The efficacy of brexpiprazole in the treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was entirely due to drug treatment on a 7-point scale, ranging from 0 to 7. Response choices were: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Higher scores indicate worse condition. Mean CGI-I scale score was determined by LOCF method.
| score on a scale | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 6 | 2.86 ± 0.95 | 2.79 ± 0.97 | 3.17 ± 1.08 |
An AE was defined as any untoward medical occurrence in a participant administered with a medicinal product that does not necessarily have a causal relationship with the treatment.
| Participants | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| AEs | 46 | 56 | 44 |
| Trial Discontinuation Due to AEs | 0 | 1 | 2 |
An AE was defined as any untoward medical occurrence in a participant administered with a medicinal product that does not necessarily have a causal relationship with the treatment. An SAE was any AE that results in the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions which is fatal, life-threatening, result in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, and requires inpatient hospitalization or prolongation of existing hospitalization. TEAE is any AE after the start of treatment or if the event was continuous from baseline, medicinal product related, or resulted in death, discontinuation, interruption or reduction of medicinal product. TEAEs were graded on a 3-point scale: 1 (Mild: Discomfort noticed, but no disruption to daily activity), 2 (Moderate: Discomfort sufficient to reduce or affect normal daily activity), and 3 (Severe: Inability to work or perform normal daily activity).
| Participants | Brexpiprazole 2 to 4 mg/Day | Aripiprazole 10 to 20 mg/Day | Placebo |
|---|---|---|---|
| TEAEs | 44 | 53 | 42 |
| Serious TEAEs | 1 | 1 | 3 |
| Mild TEAEs | 33 | 47 | 32 |
| Moderate TEAEs | 17 | 16 | 13 |
| Severe TEAEs | 2 | 0 | 1 |
Change in weight was reported, in kilograms (kg).
| kg | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Weight | 0.8 ± 2.6 | 0.5 ± 2.7 | 0.0 ± 2.2 |
Change in height was reported in centimeters (cm).
| cm | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Height | 0.2 ± 1.1 | 0.2 ± 2.9 | 0.3 ± 0.6 |
Change in BMI was reported in kilograms per square meter (kg/m\^2).
| kg/m^2 | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Body Mass Index (BMI) | 0.2 ± 1.1 | 0.3 ± 1.5 | 0.0 ± 0.9 |
Change in waist circumference was reported in 'cm'.
| cm | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Mean Change From Baseline in Waist Circumference | 0.6 ± 3.9 | -0.3 ± 4.3 | 0.0 ± 5.1 |
C-SSRS is a scale used to report at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any of the following items: actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior. The suicidal ideation total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) and the total score ranges from 0 to 25. Lower scores indicate improvement.
| Participants | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Number of Participants With At Least One Occurrence of Suicidal Behavior or Suicidal Ideation as Recorded on Columbia-Suicide Severity Rating Scale (C-SSRS) | 1 | 2 | 2 |
Potentially clinically relevant laboratory values assessed included - serum chemistry \[including blinded prolactin\], hematology, and urinalysis as defined in SAP.
| Participants | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Alanine Aminotransferase (U/L): High | 1 | 2 | 0 |
| Bilirubin (mg/dL): High | 0 | 1 | 0 |
| Cholesterol, Fasting (mg/dL): High | 2 | 3 | 0 |
| Creatine kinase (U/L): High | 5 | 4 | 1 |
| Glucose, Fasting (mg/dL): High | 16 | 15 | 9 |
| HDL Cholesterol, Fasting (mg/dL): Low | 12 | 10 | 13 |
| LDL Cholesterol, Fasting (mg/dL): High | 2 | 3 | 0 |
| Triglycerides, Fasting (mg/dL): High | 13 | 7 | 10 |
| Urate (mg/dL): High | 0 | 0 | 1 |
| Eosinophils/Leukocytes (%): High | 2 | 0 | 0 |
| Hematocrit (%): Low | 4 | 0 | 1 |
| Hemoglobin (g/dL): Low | 2 | 0 | 0 |
| Leukocytes (10^9/L): Low | 0 | 1 | 0 |
| Leukocytes (10^9/L): High | 0 | 0 | 1 |
| Protein, Urine: High | 2 | 2 | 0 |
Vital sign measurements included body weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Blood pressure measurements were made in the supine, sitting, and standing positions after the participant had been in each position for at least 3 minutes as defined in SAP.
| Participants | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| SBP Sitting (mmHg): Low | 0 | 0 | 1 |
| SBP Standing (mmHg): Low | 1 | 1 | 0 |
| SBP Supine (mmHg): Low | 0 | 0 | 1 |
| DBP Standing (mmHg): Low | 1 | 0 | 0 |
| DBP Supine (mmHg): Low | 0 | 1 | 0 |
| Weight (kg): Low | 5 | 2 | 4 |
| Weight (kg): High | 9 | 5 | 5 |
| Orthostatic Hypotension (mmHg): Low | 2 | 1 | 2 |
Twelve-lead ECG recordings were obtained after the participant was supine and at rest for at least 5 minutes as defined in SAP.
| Participants | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Rate: Bradycardia | 0 | 0 | 1 |
| Rhythm: Sinus Bradycardia | 0 | 0 | 1 |
| Rhythm: Supraventricular Premature Beat | 0 | 1 | 1 |
| Rhythm: Ventricular Premature Beat | 1 | 0 | 0 |
| ST/T Morphology: QTcF | 0 | 1 | 0 |
| ST/T Morphology: QTcN | 0 | 1 | 0 |
The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where lower scores indicate less severe condition. LS mean was determined by Analysis of Covariance (ANCOVA) model with treatment and study center as main effects and baseline value as covariate.
| score on a scale | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Change From Baseline in Simpson Angus Scale (SAS) Total Score | 0.04 ± 0.12 | 0.15 ± 0.12 | -0.03 ± 0.13 |
The AIMS assessment consists of 12 items rating the involuntary movements: Facial and oral movements (4 items), extremity movements (2 items), and trunk movements (1 item) were observed unobtrusively while the participant is at rest and the investigator also made global judgments on the participant's dyskinesias (2 items), and dental status (2 items). Severity of each item was rated on a 5-point scale, with a score of 0 (absence of symptoms) to 4 (severe condition). Total Score is the sum of the scores of all 12 items, ranging from 0 to 48, higher scores indicate severe condition. LS mean was determined by ANCOVA model with treatment and study center as main effects and baseline value as covariate.
| score on a scale | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score | -0.12 ± 0.09 | 0.05 ± 0.09 | -0.06 ± 0.09 |
The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14, higher scores indicate severe condition. LS mean was determined by ANCOVA model with treatment and study center as main effects and baseline value as covariate.
| score on a scale | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score | 0.01 ± 0.03 | 0.06 ± 0.03 | 0.01 ± 0.03 |
The UKU rating scale is a semi-structured interview used to assess the side effects of participants being treated with antipsychotic drugs. The scale is divided into 6 sub-scales: Psychic, neurological, autonomic, other, global assessment by subject, and global assessment by doctor. The scale has a total of 48 items, each item is rated on a 4-point scale (0=not present; 1=mild; 2=moderate; 3=severe), and the total score ranges from 0 to 144. Higher ratings indicate greater impairment. The severe side effects are reported in this outcome measure.
| Participants | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Psychic: Concentration Difficulties | 7 | 10 | 8 |
| Psychic: Asthenia/Lassitude | 6 | 3 | 1 |
| Psychic: Failing Memory | 2 | 2 | 4 |
| Psychic: Depression | 0 | 2 | 1 |
| Psychic: Tension/Inner Unrest | 4 | 3 | 9 |
| Psychic: Increased Duration of Sleep | 0 | 1 | 0 |
| Psychic: Reduced Duration of Sleep | 4 | 1 | 1 |
| Psychic: Increased Dream Activity | 0 | 2 | 0 |
| Psychic: Emotional Indifference | 3 | 6 | 6 |
| Neurologic: Akathisia | 1 | 1 | 0 |
| Autonomic: Nausea/Vomiting | 0 | 0 | 1 |
| Autonomic: Micturition Disturbances | 0 | 1 | 0 |
| Autonomic: Palpitations/Tachycardia | 1 | 0 | 1 |
| Autonomic: Increased Tendency to Sweating | 1 | 0 | 0 |
| Other: Weight Gain | 0 | 1 | 0 |
| Other: Amenorrhoea | 0 | 1 | 0 |
| Other: Migraine | 0 | 0 | 1 |
The NY-AACENT is used to detect changes in cognitive function subsequent to pharmacological or similar treatments for neurological or psychiatric problems, specifically designed to be used in pediatric population (ages 12 to 17), but could have been utilized with other age groups, as appropriate. Number of participants with at least one occurrence of the corresponding signs/symptoms are reported in this outcome measure.
| Participants | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| Working Memory | 88 | 79 | 83 |
| Attention/Vigilance | 98 | 90 | 91 |
| Verbal Learning | 71 | 70 | 69 |
| Visual Learning | 46 | 46 | 44 |
| Reasoning | 97 | 86 | 83 |
| Speed of Processing | 88 | 84 | 82 |
| Social Cognition | 91 | 87 | 84 |
| Any Signs/Symptoms | 100 | 91 | 92 |
Collected over From the first dose of study drug up to 21 days after the last dose of study drug (up to approximately 9 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole | 0/110 (0%) | 1/110 (0.9%) | 19/110 (17.3%) |
| Aripiprazole | 0/102 (0%) | 1/102 (1%) | 28/102 (27.5%) |
| Placebo | 0/104 (0%) | 3/104 (2.9%) | 16/104 (15.4%) |
| Event | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 1/110 | 0/102 | 2/104 |
| Psychotic DisorderPsychiatric disorders | 0/110 | 1/102 | 1/104 |
| Event | Brexpiprazole | Aripiprazole | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 5/110 | 11/102 | 5/104 |
| FatigueGeneral disorders | 2/110 | 8/102 | 0/104 |
| AkathisiaNervous system disorders | 4/110 | 7/102 | 3/104 |
| NauseaGastrointestinal disorders | 7/110 | 4/102 | 4/104 |
| HeadacheNervous system disorders | 7/110 | 5/102 | 5/104 |
Randomized sample included all participants who were randomized into the trial.
| Age, Continuous(years) | Brexpiprazole | Aripiprazole | Placebo | Total |
|---|---|---|---|---|
| Mean | 15.3 ± 1.5 | 15.3 ± 1.4 | 15.2 ± 1.4 | 15.3 ± 1.5 |
| Sex: Female, Male(Participants) | Brexpiprazole | Aripiprazole | Placebo | Total |
|---|---|---|---|---|
| Female | 58 | 57 | 51 | 166 |
| Male | 52 | 45 | 53 | 150 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole | Aripiprazole | Placebo | Total |
|---|---|---|---|---|
| Race — White | 70 | 66 | 68 | 204 |
| Race — Black or African American | 8 | 7 | 6 | 21 |
| Race — American Indian or Alaska Native | 2 | 1 | 4 | 7 |
| Race — Asian | 1 | 1 | 0 | 2 |
| Race — Other | 29 | 27 | 25 | 81 |
| Race — Missing | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole | Aripiprazole | Placebo | Total |
|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 34 | 32 | 34 | 100 |
| Ethnicity — Not Hispanic or Latino | 75 | 70 | 68 | 213 |
| Ethnicity — Other | 1 | 0 | 1 | 2 |
| Ethnicity — Missing | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Brexpiprazole | Aripiprazole | Placebo | Total |
|---|---|---|---|---|
| United States | 15 | 14 | 14 | 43 |
| France | 0 | 0 | 1 | 1 |
| Italy | 1 | 1 | 1 | 3 |
| Mexico | 32 | 31 | 32 | 95 |
| Poland | 5 | 3 | 3 | 11 |
| Romania | 6 | 6 | 6 | 18 |
| Russia | 4 | 4 | 3 | 11 |
| Serbia | 11 | 10 | 10 | 31 |
| Spain | 1 | 0 | 0 | 1 |
| Ukraine | 35 | 33 | 34 | 102 |
| Positive and Negative Syndrome Scale (PANSS) Total Score(score on a scale) | Brexpiprazole | Aripiprazole | Placebo | Total |
|---|---|---|---|---|
| Mean | 101.1 ± 14.9 | 101.0 ± 13.0 | 102.1 ± 16.3 | 101.4 ± 14.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Apr 2023, 69 months.
Results were first posted in Dec 2023, 8 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 69 months is above that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →